ARDX
Ardelyx, Inc. NASDAQ Listed Jun 19, 2014$6.05
+3.60%
vs $5.84
Mkt Cap $1.5B
52w Low $3.49
52.1% of range
52w High $8.40
50d MA $6.15
200d MA $6.12
P/E (TTM)
-23.3x
EV/EBITDA
—
P/B
8.7x
Debt/Equity
1.3x
ROE
-36.9%
P/FCF
-33.2x
RSI (14)
50.30
ATR (14)
$0.26
Beta
0.66
50d MA
$6.15
200d MA
$6.12
Avg Volume
3.4M
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
400 Fifth Avenue · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.13 | -0.15 | -15.4% | 6.33 | -5.2% | +8.7% | +6.1% | -2.3% | -0.4% | -1.7% | — |
| Feb 19, 2026 | AMC | 0.02 | 0.02 | +0.0% | 6.74 | -3.7% | -15.0% | +0.3% | +14.1% | +0.0% | +1.1% | — |
| Oct 30, 2025 | AMC | -0.06 | -0.00 | +93.3% | 5.01 | +28.3% | +21.0% | -2.3% | -5.4% | +6.3% | -5.0% | — |
| Aug 4, 2025 | AMC | -0.13 | -0.08 | +38.5% | 4.39 | +15.7% | +16.9% | +1.4% | -1.2% | +1.4% | +3.6% | — |
| May 1, 2025 | AMC | -0.10 | -0.17 | -70.0% | 5.47 | -26.0% | -24.5% | -9.4% | +5.6% | -6.3% | -1.6% | — |
| Feb 20, 2025 | AMC | 0.02 | 0.02 | +0.0% | 5.72 | +0.2% | -11.5% | +1.4% | +1.0% | -1.5% | +2.4% | — |
| Oct 31, 2024 | AMC | -0.05 | -0.00 | +93.2% | 5.87 | +2.0% | +3.7% | -3.3% | -2.9% | +13.5% | -1.7% | — |
| Aug 1, 2024 | AMC | -0.10 | -0.07 | +30.0% | 5.50 | +2.7% | +10.0% | -3.6% | +4.3% | -8.7% | +5.8% | — |
| May 2, 2024 | AMC | -0.13 | -0.11 | +15.4% | 6.79 | +23.1% | +28.4% | +4.9% | +1.7% | -8.9% | -5.0% | — |
| Feb 22, 2024 | AMC | -0.09 | -0.12 | -33.3% | 8.82 | -7.5% | -1.6% | +7.0% | +4.1% | -2.2% | -1.5% | — |
| Oct 31, 2023 | AMC | -0.11 | 0.03 | +127.3% | 3.95 | +0.0% | -0.3% | +1.8% | +0.2% | -0.5% | +1.8% | — |
| Aug 2, 2023 | AMC | -0.12 | -0.08 | +33.3% | 4.04 | +0.0% | -1.0% | -2.2% | -4.1% | +3.5% | +2.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16 | Ladenburg Thalmann | Reiterates | Buy | $16 | $5.69 | $5.74 | +0.9% | -0.4% | +3.0% | +3.6% | — | — |
| Feb 23 | Wedbush | Maintains | Outperform → Outperform | — | $5.73 | $5.66 | -1.2% | +0.3% | +14.1% | +0.0% | +1.1% | -1.2% |
| Feb 20 | BTIG | Maintains | Buy → Buy | — | $6.74 | $6.49 | -3.7% | -15.0% | +0.3% | +14.1% | +0.0% | +1.1% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.74 | $6.49 | -3.7% | -15.0% | +0.3% | +14.1% | +0.0% | +1.1% |
| Jan 29 | BTIG | Maintains | Buy → Buy | — | $7.86 | $7.89 | +0.4% | -0.1% | -2.0% | +1.3% | -0.6% | -4.7% |
| Jan 21 | Wedbush | Maintains | Outperform → Outperform | — | $7.76 | $7.79 | +0.4% | +3.0% | -0.8% | -2.0% | +0.4% | +1.2% |
| Jan 9 | BTIG | Maintains | Buy → Buy | — | $7.00 | $7.30 | +4.3% | +10.6% | -4.9% | -4.3% | -2.1% | +2.2% |
| Jan 9 | Citigroup | Maintains | Buy → Buy | — | $7.00 | $7.30 | +4.3% | +10.6% | -4.9% | -4.3% | -2.1% | +2.2% |
| Jan 9 | Piper Sandler | Upgrade | Neutral → Overweight | — | $7.00 | $7.30 | +4.3% | +10.6% | -4.9% | -4.3% | -2.1% | +2.2% |
| Nov 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.92 | $5.84 | -1.4% | -5.4% | +6.2% | -5.0% | -1.1% | +1.1% |
| Nov 3 | Citigroup | Maintains | Buy → Buy | — | $6.06 | $6.07 | +0.2% | -2.3% | -5.4% | +6.2% | -5.0% | -1.1% |
| Oct 31 | TD Cowen | Maintains | Buy → Buy | — | $5.01 | $6.43 | +28.3% | +21.0% | -2.3% | -5.4% | +6.3% | -5.0% |
| Aug 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.13 | $5.13 | +0.0% | +1.4% | -1.2% | +1.4% | +3.6% | +3.7% |
| Aug 5 | Wedbush | Maintains | Outperform → Outperform | — | $4.39 | $5.08 | +15.7% | +16.9% | +1.4% | -1.2% | +1.4% | +3.6% |
| Aug 5 | Raymond James | Maintains | Outperform → Outperform | — | $4.39 | $5.08 | +15.7% | +16.9% | +1.4% | -1.2% | +1.4% | +3.6% |
| May 2 | Citigroup | Maintains | Buy → Buy | — | $5.47 | $4.05 | -26.0% | -24.5% | -9.4% | +5.6% | -6.3% | -1.6% |
| Feb 21 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $5.72 | $5.73 | +0.2% | -11.5% | +1.4% | +1.0% | -1.5% | +2.4% |
| Feb 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $5.72 | $5.73 | +0.2% | -11.5% | +1.4% | +1.0% | -1.5% | +2.4% |
| Jan 27 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.52 | $5.52 | +0.0% | -0.9% | +0.4% | -0.2% | -2.2% | +0.0% |
| Jan 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $5.35 | $5.33 | -0.4% | -3.6% | -2.9% | -2.0% | +2.9% | +9.1% |
| Jan 2 | Jefferies | Maintains | Buy → Buy | — | $5.07 | $5.03 | -0.8% | +1.0% | -2.9% | +0.6% | +8.2% | -1.3% |
| Nov 11 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $5.07 | $4.89 | -3.6% | -3.6% | -6.1% | -2.0% | +4.7% | +5.5% |
| Nov 4 | Citigroup | Maintains | Buy → Buy | — | $6.09 | $5.96 | -2.1% | -3.3% | -2.9% | +13.5% | -1.7% | -20.5% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.87 | $5.99 | +2.0% | +3.7% | -3.3% | -2.9% | +13.5% | -1.7% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.05 | $5.45 | -9.9% | -3.6% | +4.3% | -8.7% | +5.8% | -2.9% |
| Aug 2 | Wedbush | Maintains | Outperform → Outperform | — | $5.50 | $5.65 | +2.7% | +10.0% | -3.6% | +4.3% | -8.7% | +5.8% |
| Aug 2 | Citigroup | Maintains | Buy → Buy | — | $5.50 | $5.65 | +2.7% | +10.0% | -3.6% | +4.3% | -8.7% | +5.8% |
| Jul 18 | Wedbush | Maintains | Outperform → Outperform | — | $5.75 | $5.80 | +0.9% | -4.5% | +0.4% | +3.4% | -0.2% | -1.2% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.75 | $5.80 | +0.9% | -4.5% | +0.4% | +3.4% | -0.2% | -1.2% |
| Jul 3 | Citigroup | Maintains | Buy → Buy | — | $5.28 | $5.53 | +4.7% | +0.8% | -0.6% | +3.0% | +2.0% | +0.0% |
| May 24 | Wedbush | Maintains | Outperform → Outperform | — | $7.44 | $7.33 | -1.5% | -9.3% | +2.2% | -4.2% | +2.6% | +1.2% |
| May 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.44 | $7.33 | -1.5% | -9.3% | +2.2% | -4.2% | +2.6% | +1.2% |
| May 3 | Citigroup | Maintains | Buy → Buy | — | $6.79 | $8.36 | +23.1% | +28.4% | +4.9% | +1.7% | -8.9% | -5.0% |
| May 3 | Wedbush | Maintains | Outperform → Outperform | — | $6.79 | $8.36 | +23.1% | +28.4% | +4.9% | +1.7% | -8.9% | -5.0% |
| Apr 17 | Wedbush | Maintains | Outperform → Outperform | — | $6.71 | $6.83 | +1.8% | -2.4% | -1.7% | +0.6% | +0.5% | -1.8% |
| Feb 23 | Wedbush | Maintains | Outperform → Outperform | — | $8.82 | $8.16 | -7.5% | -1.6% | +7.0% | +4.1% | -2.2% | -1.5% |
| Feb 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.82 | $8.16 | -7.5% | -1.6% | +7.0% | +4.1% | -2.2% | -1.5% |
| Jan 12 | Wedbush | Maintains | Outperform → Outperform | — | $8.72 | $8.81 | +1.0% | +3.6% | -2.8% | -3.0% | -5.6% | +3.0% |
| Jan 10 | Citigroup | Maintains | Buy → Buy | — | $9.10 | $9.18 | +0.9% | -0.2% | -4.0% | +3.6% | -2.8% | -3.0% |
| Jan 9 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $8.18 | $8.17 | -0.1% | +11.2% | -0.2% | -4.0% | +3.6% | -2.8% |
| Dec 1 | Wedbush | Maintains | Outperform → Outperform | — | $4.51 | $4.50 | -0.2% | +5.5% | +4.2% | +1.2% | +2.4% | +3.1% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.95 | $3.95 | +0.0% | -0.3% | +1.8% | +0.2% | -0.5% | +1.8% |
| Sep 13 | Wedbush | Maintains | Outperform → Outperform | — | $4.83 | $4.86 | +0.6% | -5.0% | +1.5% | -2.4% | -8.4% | -3.8% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.73 | $4.77 | +0.8% | +2.1% | -5.0% | +1.5% | -2.4% | -8.4% |
| Aug 25 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $3.51 | $3.69 | +5.1% | +12.3% | +7.9% | -1.2% | +1.0% | +0.5% |
| Aug 3 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $4.04 | $4.04 | +0.0% | -1.0% | -2.2% | -4.1% | +3.5% | +2.1% |
| Apr 17 | Wedbush | Maintains | Outperform → Outperform | — | $4.71 | $4.67 | -0.8% | +4.5% | -0.6% | +0.2% | -2.4% | +3.6% |
| Mar 3 | Wedbush | Upgrade | Neutral → Outperform | — | $2.89 | $3.40 | +17.6% | +32.2% | +2.1% | +1.0% | +3.3% | -6.1% |
| Dec 30 | Citigroup | Maintains | Buy → Buy | — | $2.53 | $2.59 | +2.4% | +12.6% | -6.0% | +4.9% | -2.1% | +4.4% |
| Nov 17 | Piper Sandler | Upgrade | Neutral → Overweight | — | $1.22 | $1.97 | +61.5% | +41.0% | +20.9% | -0.5% | -10.6% | -4.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | RAAB MICHAELDir/Off | President & CEO | Sell | 41,666 | $5.67 | $236K | 1,699,200 | +3.60% | — |
| May 15, 2026 | RAAB MICHAELDir/Off | President & CEO | Sell | 41,666 | $6.28 | $262K | 1,774,781 | +2.96% | -1.28% |
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Millennium Management | 17,842,370 | $107M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 10,365,512 | $62M | New | Mar 2026 |
| 3 | Janus Henderson Group Plc | 8,371,234 | $50M | New | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 6,661,693 | $40M | New | Mar 2026 |
| 5 | Nuveen, Llc | 5,234,683 | $31M | Added | Mar 2026 |
| 6 | Morgan Stanley | 4,717,612 | $28M | Reduced | Dec 2025 |
| 7 | Two Sigma Investments, Lp | 4,274,043 | $26M | Added | Mar 2026 |
| 8 | Citadel Advisors Llc | 3,464,774 | $21M | Added | Mar 2026 |
| 9 | Point72 Asset Management | 2,984,261 | $18M | Added | Mar 2026 |
| 10 | Aqr Capital Management Llc | 2,439,450 | $15M | Added | Mar 2026 |
| 11 | Qube Research & Technologies Ltd | 2,435,548 | $15M | Added | Mar 2026 |
| 12 | Bank Of America Corp /de/ | 2,336,994 | $14M | Reduced | Mar 2026 |
| 13 | Northern Trust Corp | 2,071,047 | $12M | Added | Mar 2026 |
| 14 | Jane Street Group, Llc | 2,060,667 | $12M | Reduced | Dec 2025 |
| 15 | Marshall Wace, Llp | 1,600,857 | $10M | Reduced | Mar 2026 |
| 16 | First Trust Advisors Lp | 1,498,798 | $9M | Added | Mar 2026 |
| 17 | Renaissance Technologies Llc | 1,272,441 | $8M | Reduced | Mar 2026 |
| 18 | Susquehanna International Group, Llp | 701,968 | $4M | Reduced | Mar 2026 |
| 19 | Bank Of New York Mellon Corp | 700,783 | $4M | Reduced | Mar 2026 |
| 20 | Bnp Paribas Financial Markets | 698,744 | $4M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.49B
Enterprise Value
$1.40B
P/E (TTM)
-23.27x
Forward P/E
1234.69x
PEG Ratio
-0.43x
P/B
8.74x
P/S
3.58x
P/FCF
-33.16x
EV/EBITDA
—
Shares Out
241.0M
Financials (TTM)
Revenue
$407.3M
Net Income
-$61.6M
EBITDA
-$29.2M
Free Cash Flow
-$44.0M
Op Cash Flow
-$42.5M
EPS Basic
$-0.26
EPS Diluted
$-0.26
EPS Forward
$0.00
Gross Margin
90.3%
Op Margin
-10.1%
Net Margin
-15.1%
Balance Sheet
Total Assets
$501.6M
Total Liab.
$334.7M
Total Equity
$166.9M
Cash
$264.7M
LT Debt
$206.5M
Book Value/Sh
$0.69
Debt/Equity
1.27x
Current Ratio
4.31
Quick Ratio
4.11
Returns & Growth
ROE
-36.9%
ROA
-12.3%
ROIC
-9.9%
Rev Growth YoY
+22.1%
EPS Growth YoY
-52.9%
Price Returns
2W
-6.5%
1M
-4.6%
3M
-7.8%
6M
+4.1%
12M
+64.6%
Technicals
52W High
$8.40
52W Low
$3.49
50d MA
$6.15
200d MA
$6.12
RSI (14)
50.30
ATR (14)
$0.26
Beta
0.66
Avg Volume
3.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$17.00
High
$19.00
Low
$15.00
Median
$17.00
Data updated apr 24, 2026 6:48pm
· Source: financialmodelingprep.com